COMETRIQ (cabozantinib), tyrosine kinase inhibitor

COMETRIQ has Marketing Authorisation in the treatment of adults with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).

For patients in whom rearranged during transfection (RET) mutation status is not known or is negative, a possible lower benefit must be considered.

Its efficacy versus placebo has been demonstrated in an improvement in progression-free survival (+ 7.2 months), but not in overall survival.

COMETRIQ (cabozantinib) is a current alternative to vandetanib (CAPRELSA) in the first-line treatment of patients with progressive advanced or metastatic MTC.